Bob W Van Oosten

List of Publications by Year
in descending order

57 papers	4,744 citations	159585 30 h-index	138484 58 g-index
61 all docs	61 docs citations	61 times ranked	4708 citing authors

#	Article	IF	Citations
1	Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology, 1996, 47, 1531-1534.	1.1	705
2	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet, The, 2018, 391, 1263-1273.	13.7	684
3	Accumulation of hypointense lesions ("black holes") on T ₁ spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology, 1996, 47, 1469-1476.	1.1	440
4	Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled MR-monitored phase II trial. Neurology, 1997, 49, 351-357.	1.1	247
5	Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Annals of Neurology, 1999, 45, 695-703.	5.3	247
6	Fecal Microbiota Transplantation in Neurological Disorders. Frontiers in Cellular and Infection Microbiology, 2020, 10, 98.	3.9	221
7	TNF-Î± promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. Journal of Neuroimmunology, 1997, 72, 149-153.	2.3	214
8	PML in a Patient Treated with Dimethyl Fumarate from a Compounding Pharmacy. New England Journal of Medicine, 2013, 368, 1658-1659.	27.0	181
9	PML in a Patient without Severe Lymphocytopenia Receiving Dimethyl Fumarate. New England Journal of Medicine, 2015, 372, 1474-1476.	27.0	144
10	Natalizumab drug holiday in multiple sclerosis: Poorly Tolerated. Annals of Neurology, 2010, 68, 392-395.	5.3	120
11	No association of abnormal cranial venous drainage with multiple sclerosis: a magnetic resonance venography and flow-quantification study. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 429-435.	1.9	119
12	Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans.. Journal of Clinical Investigation, 1997, 99, 2225-2231.	8.2	85
13	Tumefactive multiple sclerosis lesions under fingolimod treatment. Neurology, 2012, 79, 2000-2003.	1.1	79
14	Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases. Journal of Neurology, 2017, 264, 1155-1164.	3.6	77
15	MRI pattern in asymptomatic natalizumab-associated PML. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 793-798.	1.9	75
16	Multiple sclerosis patients show a highly significant decrease in alpha band interhemispheric synchronization measured using MEG. NeuroImage, 2006, 29, 783-788.	4.2	73
17	Interleukin-1 receptor antagonist gene polymorphism and multiple sclerosis. Lancet, The, 1995, 346, 979-980.	13.7	69
18	Development of Hypointense Lesions on T1-Weighted Spin-Echo Magnetic Resonance Images in Multiple Sclerosis. Archives of Neurology, 1999, 56, 345.	4.5	63

#	Article	IF	Citations
19	Increased Production of Tumor Necrosis Factor Î±, and Not of Interferon Î³, Preceding Disease Activity in Patients With Multiple Sclerosis. Archives of Neurology, 1998, 55, 793.	4.5	60
20	What Went Wrong? the Flawed Concept of Cerebrospinal Venous Insufficiency. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 657-668.	4.3	51
21	CLIPPERS and its mimics: evaluation of new criteria for the diagnosis of CLIPPERS. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1027-1038.	1.9	51
22	Cognitive behavioral therapy positively affects fatigue in patients with multiple sclerosis: Results of a randomized controlled trial. Multiple Sclerosis Journal, 2017, 23, 1542-1553.	3.0	47
23	Case Reports of PML in Patients Treated for Psoriasis. New England Journal of Medicine, 2013, 369, 1080-1082.	27.0	45
24	Effectiveness of energy conservation management on fatigue and participation in multiple sclerosis: A randomized controlled trial. Multiple Sclerosis Journal, 2017, 23, 1527-1541.	3.0	45
25	Heterogeneous imaging characteristics of JC virus granule cell neuronopathy (GCN): a case series and review of the literature. Journal of Neurology, 2015, 262, 65-73.	3.6	44
26	The effectiveness of aerobic training, cognitive behavioural therapy, and energy conservation management in treating MS-related fatigue: the design of the TREFAMS-ACE programme. Trials, 2013, 14, 250.	1.6	41
27	Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases. Methods, 2012, 56, 508-513.	3.8	38
28	Personalized extended interval dosing of natalizumab in MS. Neurology, 2020, 95, e745-e754.	1.1	36
29	Second intravenous immunoglobulin dose in patients with Guillain-BarrÃ© syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 275-283.	10.2	34
30	Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic. Multiple Sclerosis Journal, 2022, 28, 1121-1125.	3.0	34
31	Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist. Multiple Sclerosis Journal, 2004, 10, 330-332.	3.0	33
32	Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?. Journal of Neurology, 2014, 261, 1139-1143.	3.6	30
33	A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis. Multiple Sclerosis Journal, 1996, 1, 339-342.	3.0	27
34	Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology, 2011, 76, 574-576.	1.1	27
35	Multiple Sclerosis Therapy. Drugs, 1995, 49, 200-212.	10.9	22
36	A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis. Journal of Neuroimmunology, 1996, 66, 49-55.	2.3	22

#	Article	IF	Citations
37	Case for a new corticosteroid treatment trial in optic neuritis: review of updated evidence. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 9-14.	1.9	22
38	Real-Time Assessment of Fatigue in Patients With Multiple Sclerosis: How Does It Relate to Commonly Used Self-Report Fatigue Questionnaires?. Archives of Physical Medicine and Rehabilitation, 2016, 97, 1887-1894.e1.	0.9	19
39	Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy. Multiple Sclerosis Journal, 2015, 21, 481-484.	3.0	18
40	Emerging safety issues in alemtuzumab-treated MS patients. Multiple Sclerosis Journal, 2019, 25, 1206-1208.	3.0	18
41	PML in Patients Treated with Dimethyl Fumarate. New England Journal of Medicine, 2015, 373, 582-584.	27.0	17
42	Brain miliary enhancement. Neuroradiology, 2020, 62, 283-300.	2.2	16
43	Effect of rimonabant on weight reduction and cardiovascular risk. Lancet, The, 2005, 366, 367-368.	13.7	15
44	Disease activity following pregnancy-related discontinuation of natalizumab in MS. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e424.	6.0	15
45	Time is vision in recurrent optic neuritis. Brain Research, 2017, 1673, 95-101.	2.2	14
46	Choosing Drug Therapy for Multiple Sclerosis. Drugs, 1998, 56, 555-569.	10.9	13
47	Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy. Annals of Neurology, 2019, 86, 322-324.	5.3	11
48	The role of appraisal and coping style in relation with societal participation in fatigued patients with multiple sclerosis: a cross-sectional multiple mediator analysis. Journal of Behavioral Medicine, 2016, 39, 855-865.	2.1	9
49	Steroid-responsive edema in CAA-related inflammation. Journal of Neurology, 2009, 256, 285-286.	3.6	8
50	Interleukin-2 therapy does not exacerbate multiple sclerosis. Neurology, 1997, 49, 633-634.	1.1	5
51	The role of spinal cord imaging in the diagnosis of multiple sclerosis. Nature Clinical Practice Neurology, 2006, 2, 283-286.	2.5	3
52	Neuromyelitis optica spectrum disorder mimicking multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 17, 54-56.	2.0	2
53	Anti-natalizumab antibodies during 8Âyears of natalizumab treatment: effect on natalizumab concentration and Î±4-integrin receptor saturation. Journal of Neurology, 2019, 266, 1804-1805.	3.6	2
54	Patientsâ€™ expectations of autologous hematopoietic stem cell transplantation as a treatment for MS. Multiple Sclerosis and Related Disorders, 2020, 37, 101467.	2.0	2

#	Article	IF	Citations
55	Natalizumab concentrations during pregnancy in three patients with multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 323-326.	3.0	1
56	Whipple's disease in mentally retarded patients: Report of two cases. Scandinavian Journal of Infectious Diseases, 2007, 39, 1071-1073.	1.5	0
57	Response: Brain miliary enhancement. Neuroradiology, 2020, 62, 547-547.	2.2	0